Related references
Note: Only part of the references are listed.Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
The immunomodulatory effects of endocrine therapy in breast cancer
Huanhuan Huang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)
Tumor mutational burden as a predictor of immunotherapy response in breast cancer
Tess A. O’Meara et al.
Oncotarget (2021)
Chemokines and the immune response to cancer
Aleksandra J. Ozga et al.
IMMUNITY (2021)
Macrophage Biology and Mechanisms of Immune Suppression in Breast Cancer
Anita K. Mehta et al.
FRONTIERS IN IMMUNOLOGY (2021)
The Immunology of Hormone Receptor Positive Breast Cancer
Jonathan Goldberg et al.
FRONTIERS IN IMMUNOLOGY (2021)
G Protein-Coupled Estrogen Receptor in Cancer and Stromal Cells: Functions and Novel Therapeutic Perspectives
Richard A. Pepermans et al.
CELLS (2021)
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial
Lajos Pusztai et al.
CANCER CELL (2021)
Enhancing programmed cell death protein 1 axis inhibition in head and neck squamous cell carcinoma: Combination immunotherapy
Ioannis A. Vathiotis et al.
CANCER TREATMENT REVIEWS (2021)
Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti-PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer
Paula Gonzalez-Ericsson et al.
CLINICAL CANCER RESEARCH (2021)
Programmed Death-Ligand 1 as a Regulator of Tumor Progression and Metastasis
Ioannis A. Vathiotis et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Exploiting off-target effects of estrogen deprivation to sensitize estrogen receptor negative breast cancer to immune killing
Benjamin Wolfson et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Endogenous and Therapeutic Estrogens: Maestro Conductors of the Microenvironment of ER plus Breast Cancers
Linda A. Schuler et al.
CANCERS (2021)
Biomarkers of therapeutic response with immune checkpoint inhibitors
Poorva Bindal et al.
ANNALS OF TRANSLATIONAL MEDICINE (2021)
The clinical and molecular significance associated with STING signaling in breast cancer
Eileen E. Parkes et al.
NPJ BREAST CANCER (2021)
Steroid Hormone Receptor and Infiltrating Immune Cell Status Reveals Therapeutic Vulnerabilities of ESR1-Mutant Breast Cancer
Michelle M. Williams et al.
CANCER RESEARCH (2021)
Optimized immunohistochemical detection of estrogen receptor beta using two validated monoclonal antibodies confirms its expression in normal and malignant breast tissues
John R. Hawse et al.
BREAST CANCER RESEARCH AND TREATMENT (2020)
Clonality, Antigen Recognition, and Suppression of CD8+ T Cells Differentially Affect Prognosis of Breast Cancer Subtypes
Dora Hammerl et al.
CLINICAL CANCER RESEARCH (2020)
Immune Checkpoint Profiles in Luminal B Breast Cancer (Alliance)
Meenakshi Anurag et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2020)
Prevalence and mutational determinants of high tumor mutation burden in breast cancer
R. Barroso-Sousa et al.
ANNALS OF ONCOLOGY (2020)
Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study
P. Schmid et al.
ANNALS OF ONCOLOGY (2020)
The therapeutic potential of targeting tryptophan catabolism in cancer
Christiane A. Opitz et al.
BRITISH JOURNAL OF CANCER (2020)
Programmed death-ligand 1 gene expression is a prognostic marker in early breast cancer and provides additional prognostic value to 21-gene and 70-gene signatures in estrogen receptor-positive disease
Ioannis Zerdes et al.
MOLECULAR ONCOLOGY (2020)
Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial
Rita Nanda et al.
JAMA ONCOLOGY (2020)
Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2-negative endocrine-refractory metastatic breast cancer
Ami N. Shah et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Cancer type-dependent correlations between TP53 mutations and antitumor immunity
Lin Li et al.
DNA REPAIR (2020)
Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer
Manuela Terranova-Barberio et al.
NATURE COMMUNICATIONS (2020)
Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial
Sara M. Tolaney et al.
JAMA ONCOLOGY (2020)
Estrogen Receptor Beta (ERβ): A Ligand Activated Tumor Suppressor
Rahul Mal et al.
FRONTIERS IN ONCOLOGY (2020)
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
Javier Cortes et al.
LANCET (2020)
The therapeutic response of ER+/HER2- breast cancers differs according to the molecular Basal or Luminal subtype
Francois Bertucci et al.
NPJ BREAST CANCER (2020)
Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: analysis from a nationwide phase II DBCG trial
Signe Korsgaard Skriver et al.
BREAST CANCER RESEARCH (2020)
Tumor-Associated Macrophages Induce Endocrine Therapy Resistance in ER plus Breast Cancer Cells
Andres M. Castellaro et al.
CANCERS (2019)
A Single-Cell Atlas of the Tumor and Immune Ecosystem of Human Breast Cancer
Johanna Wagner et al.
CELL (2019)
The Immune Microenvironment in Hormone Receptor-Positive Breast Cancer Before and After Preoperative Chemotherapy
Adrienne G. Waks et al.
CLINICAL CANCER RESEARCH (2019)
Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
S. Adams et al.
ANNALS OF ONCOLOGY (2019)
Biological Consequences of MHC-II Expression by Tumor Cells in Cancer
Margaret L. Axelrod et al.
CLINICAL CANCER RESEARCH (2019)
Ten-year recurrence rates for breast cancer subtypes in the Netherlands: A large population-based study
Marissa C. van Maaren et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Immune Tumor Microenvironment in Breast Cancer and the Participation of Estrogens and Its Receptors Into Cancer Physiopathology
Mariana Segovia-Mendoza et al.
FRONTIERS IN IMMUNOLOGY (2019)
Estrogen receptor variants in ER-positive basal-type breast cancers responding to therapy like ER-negative breast cancers
Floris H. Groenendijk et al.
NPJ BREAST CANCER (2019)
Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy
Bruno Valentin Sinn et al.
BREAST CANCER RESEARCH (2019)
Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes
Marcelo Sobral-Leite et al.
BREAST CANCER RESEARCH (2019)
Loss of Human Leukocyte Antigen Class I Expression Is Associated with Poor Prognosis in Patients with Advanced Breast Cancer
Hong Sik Park et al.
JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE (2019)
Differences in Breast Cancer Survival by Molecular Subtypes in the United States
Nadia Howlader et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2018)
Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer
Hope S. Rugo et al.
CLINICAL CANCER RESEARCH (2018)
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
Carsten Denkert et al.
LANCET ONCOLOGY (2018)
TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
Daniele V. F. Tauriello et al.
NATURE (2018)
APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer
Shixiang Wang et al.
ONCOGENE (2018)
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan et al.
NATURE (2018)
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors
Diana Miao et al.
NATURE GENETICS (2018)
Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival
Marcelo Sobral-Leite et al.
ONCOIMMUNOLOGY (2018)
Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers
Takahiro Watanabe et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
Luc Y. Dirix et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
CD68, CD163, and matrix metalloproteinase 9 (MMP-9) co-localization in breast tumor microenvironment predicts survival differently in ER-positive and -negative cancers
Vasiliki Pelekanou et al.
BREAST CANCER RESEARCH (2018)
Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer
Rico D. Bense et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Tumor Cell-Independent Estrogen Signaling Drives Disease Progression through Mobilization of Myeloid-Derived Suppressor Cells
Nikolaos Svoronos et al.
CANCER DISCOVERY (2017)
Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer
Rico D. Bense et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor positive breast cancers
Uma Krishnamurti et al.
HUMAN PATHOLOGY (2017)
Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype
W. Fraser Symmans et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
CDK4/6 inhibition triggers anti-tumour immunity
Shom Goel et al.
NATURE (2017)
cGAS is essential for the antitumor effect of immune checkpoint blockade
Hua Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes and residual cancer burden
Yuka Asano et al.
BMC CANCER (2017)
Comprehensive Analysis of Hypermutation in Human Cancer
Brittany B. Campbell et al.
CELL (2017)
Tumor-infiltrating lymphocytes in breast cancer according to tumor subtype: Current state of the art
Cinzia Solinas et al.
BREAST (2017)
Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary analysis of the ARTemis trial
H. R. Ali et al.
ANNALS OF ONCOLOGY (2017)
High tumor-infiltrating FoxP3+ T cells predict poor survival in estrogen receptor-positive breast cancer: A meta-analysis
F. Qian et al.
EJSO (2017)
Clinical relevance of host immunity in breast cancer: from TILs to the clinic
Peter Savas et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment
Angel Guerrero-Zotano et al.
CANCER AND METASTASIS REVIEWS (2016)
New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer
Sherry X. Yang et al.
CANCER TREATMENT REVIEWS (2016)
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Rita Nanda et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting
Luisa Carbognin et al.
ONCOLOGIST (2016)
Differential expression of major histocompatibility complex class I in subtypes of breast cancer is associated with estrogen receptor and interferon signaling
Hee Jin Lee et al.
ONCOTARGET (2016)
Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes A Systematic Review
Sasha E. Stanton et al.
JAMA ONCOLOGY (2016)
Clinical significance of tumor-infiltrating lymphocytes in breast cancer
Sasha E. Stanton et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Concomitant KIT/BRAF and PDGFRA/BRAF mutations are rare events in gastrointestinal stromal tumors
Sabrina Rossi et al.
ONCOTARGET (2016)
Clinicopathological and prognostic significance of FOXP3+tumor infiltrating lymphocytes in patients with breast cancer: a meta-analysis
Daqing Jiang et al.
BMC CANCER (2015)
CCL2 and CCL5 Are Novel Therapeutic Targets for Estrogen-Dependent Breast Cancer
Susanne Svensson et al.
CLINICAL CANCER RESEARCH (2015)
Defining Breast Cancer Intrinsic Subtypes by Quantitative Receptor Expression
Maggie C. U. Cheang et al.
ONCOLOGIST (2015)
Tamoxifen augments the innate immune function of neutrophils through modulation of intracellular ceramide
Ross Corriden et al.
NATURE COMMUNICATIONS (2015)
STING: infection, inflammation and cancer
Glen N. Barber
NATURE REVIEWS IMMUNOLOGY (2015)
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
S. Loi et al.
ANNALS OF ONCOLOGY (2014)
Association between CD8+T-cell infiltration and breast cancer survival in 12 439 patients
H. R. Ali et al.
ANNALS OF ONCOLOGY (2014)
Somatic mutation load of estrogen receptor-positive breast tumors predicts overall survival: an analysis of genome sequence data
Svasti Haricharan et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Differential expression of estrogen receptor α, β1, and β2 in lobular and ductal breast cancer
Bo Huang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Prognostic significance of FOXP3+tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration
Shuzhen Liu et al.
BREAST CANCER RESEARCH (2014)
PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients
Karin Beelen et al.
BREAST CANCER RESEARCH (2014)
Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment
Karin Beelen et al.
BREAST CANCER RESEARCH (2014)
CD4+ follicular helper T cell infiltration predicts breast cancer survival
Chunyan Gu-Trantien et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Prospective Validation of Immunological Infiltrate for Prediction of Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer - A Substudy of the Neoadjuvant GeparQuinto Trial
Yasmin Issa-Nummer et al.
PLOS ONE (2013)
The Genomic Landscape of Breast Cancer as a Therapeutic Roadmap
Matthew J. Ellis et al.
CANCER DISCOVERY (2013)
Whole-genome analysis informs breast cancer response to aromatase inhibition
Matthew J. Ellis et al.
NATURE (2012)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
Carsten Denkert et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Tamoxifen Induces Expression of Immune Response-Related Genes in Cultured Normal Human Mammary Epithelial Cells
Laura J. Schild-Hay et al.
CANCER RESEARCH (2009)
Immunomodulation of FOXP3+ Regulatory T Cells by the Aromatase Inhibitor Letrozole in Breast Cancer Patients
Daniele Generali et al.
CLINICAL CANCER RESEARCH (2009)
PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer
C. A. Crane et al.
ONCOGENE (2009)
Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse
Gaynor J. Bates et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
TGFβ:: the molecular Jekyll and Hyde of cancer
Brian Bierie et al.
NATURE REVIEWS CANCER (2006)
Total loss of MHC class I is an independent indicator of good prognosis in breast cancer
Z Madjd et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Share Paper
